22nd Century Group, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how 22nd Century Group performed this year. We’ll skip the dense legal filings and break down the company’s status so you can decide if it fits your investment goals.

1. What does this company do?

22nd Century Group is a biotech-focused tobacco company. Their main product is "VLN," a cigarette with 95% less nicotine than standard brands, which received FDA authorization as a modified-risk product in late 2021.

They also operate a contract manufacturing business in North Carolina, producing cigarettes and little cigars for other brand owners. This manufacturing work currently generates the majority of the company's revenue, while the VLN brand remains in the early stages of market development.

2. Financial performance

The company’s financial results have declined recently. In 2023, they reported $30.1 million in revenue, down from $36.1 million in 2022. Profit margins are currently negative, as the cost of production often exceeds the revenue generated.

The company recorded a loss of $65.4 million in 2023. Management has noted "substantial doubt" regarding the company’s ability to continue as a going concern, as they are currently burning through cash and require additional capital to fund operations for the coming year.

3. Major wins and challenges

• Survival Mode: The company is focused on maintaining its stock exchange listing and avoiding bankruptcy. This has included a 1-for-15 reverse stock split in 2023 and ongoing efforts to raise capital through stock sales.
• Competitive Landscape: They face significant competition from industry giants like Altria and Reynolds American, which possess much larger marketing budgets. 22nd Century’s limited scale restricts VLN to small test markets.
• Operational Concentration: The manufacturing business relies on a small number of customers. The loss of any single major client would result in a significant decrease in total revenue.

4. Financial health

The company’s financial position is fragile. They hold less than $5 million in cash against significant debt. With a market value of roughly $3.5 million as of mid-2025, the company’s liabilities exceed its assets. To cover ongoing expenses, the company has relied on issuing new shares, which dilutes the value of existing holdings.

5. Key risks

• Going Concern Risk: The company is not currently profitable and requires consistent external funding to remain operational.
• Dilution: Frequent issuance of new shares to raise cash reduces the ownership percentage and value for current shareholders.
• Regulatory Environment: The company’s core strategy is tied to FDA regulations. Any changes in how the agency regulates nicotine could negatively impact the viability of the VLN product line.
• Market Volatility: The stock price is subject to high volatility and the risk of delisting if the share price remains below exchange requirements.

6. Future outlook

The company’s long-term strategy depends on the potential for broader FDA mandates requiring the industry to lower nicotine levels, which would create a larger market for their technology. In the immediate term, the company must successfully scale VLN sales while managing its cash position to avoid insolvency.

Note: This is a high-risk situation. If you are considering an investment, weigh the potential for a turnaround against the significant risk of capital loss.